SOLICITATION NOTICE
R -- Evaluation of Human Papillomavirus (HPV) Methylation to Triage HPV-Positive Women
- Notice Date
- 8/5/2013
- Notice Type
- Presolicitation
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- NCI-130100-HN
- Archive Date
- 8/20/2013
- Point of Contact
- Huy Nguyen, Phone: 2402765570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
anh-huy.nguyen@nih.gov, ninans@mail.nih.gov
(anh-huy.nguyen@nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive Room 1E154 Bethesda, MD 20892 Description: The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG) plans to procure on a sole source basis with the Albert Einstein College of Medicine of Yeshiva University, services to perform bisulfite modification of 1,000 cervical specimens, run up to 10 type-specific polymerase chain reaction (PCR) assays, and to perform pyrosequencing of all specimens that had positive results in the type-specific PCRs. The products herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1(b)(2). The North American Industry Classification System code is 611310 and the small business standard is $25.5 million dollars.. Only one (1) award will be made as a result of this solicitation. This will be awarded as a Firm Fixed Price (FFP) type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The DCEG has a requirement to conduct methylation analyses of a large number of carcinogenic HPV genotypes. Primary HPV screening can be effective at increasing detection of cervical cancer precursors (CIN3), while allowing extending screening intervals among women testing negative for HPV DNA. Most HPV infections are transient and do not require intervention. Triage tests are needed to decide who among the HPV-positive women requires immediate management vs. follow-up. The NCI recently discovered that regions of the HPV genome of several important carcinogenic types are highly methylated in women with CIN3 compared to women with transient infections. The NCI plans to evaluate methylation of the eight most important carcinogenic types to study risk stratification in a large population of HPV-positive women. The proposed vendor is the only laboratory known that has developed and successfully validated HPV methylation assays for eight carcinogenic HPV types. The assays have been successfully used in previous collaborations. Specifically, the assays have been successfully used in specimens from the study where the assay will be conducted for this project. While it would be theoretically possible to develop similar assays at a different laboratory, this would require substantial effort, funding, and additional validation in the NCI study and would delay the project substantially and waste valuable specimens for assay validation. The Contractor shall: •Perform bisulfite modification of 1,000 cervical specimens •Run up to 10 type-specific PCR assays in 1,000 specimens (10,000 assays) •Perform pyrosequencing of all specimens that had positive results in the type-specific PCRs •Report the results of the HPV genotyping and the methylation status for all 1,000 specimens to the Contracting Officer Representative (COR) by email in an Excel sheet. Deliverables: •A summary of specimens analyzed with individual results and interpretation (HPV genotyping status and HPV methylation status) shall be emailed to the COR upon their completion. •The completeness and quality of HPV methylation analysis will be inspected and approved by the COR within two (2) weeks of reporting by the Contractor. Period of Performance: •12 months from the date of award. This is not a solicitation for competitive quotations. However, if any interested party, particularly small businesses, believe they can meet the above requirement, they may submit a statement of capabilities via fax or email. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. The capability statement must be received in the NCI contracting office on or before 4:00 PM EST on August 19, 2013. All questions must be in writing and can be faxed (240) 276-5399 or emailed to Anh-Huy Nguyen, Contract Specialist at anh-huy.nguyen@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) www.sam.gov. No collect calls will be accepted. Please reference solicitation number NCI-130100-HN on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-130100-HN/listing.html)
- Record
- SN03137519-W 20130807/130805234743-5076fb6682659f3434642db5bce55326 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |